NCT00381251View on ClinicalTrials.gov

Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.

PHASE1CompletedINTERVENTIONAL

Timeline

Start Date

September 30, 2006

Study Completion Date

January 31, 2007

Conditions

Postmenopausal OsteoporosisPostmenopause

Interventions

DRUG

Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00381251 - Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation. | Biotech Hunter | Biotech Hunter